Huasheng**, December 12 (Correspondent Dai Bing) Recently, the China Association for the Promotion of International Exchange in Health Care held the 2023 Huaxia Medical Science and Technology Award Presentation Conference in Nanjing. The team of Professor Chen Zhiyi of Changsha Central Hospital affiliated to the University of South China won the second prize of the Huaxia Medical Science and Technology Award - Science and Technology Award for the "Construction and Technological Innovation of Image-mediated Targeted and Controlled Release of Malignant Tumors" declared by the University of South China as the first completion unit.
Molecular targeting is one of the new methods of malignant tumors in recent years, but targeted drugs often have different degrees of toxicity, however, it is difficult for biological methods to carry out precise in vivo control and real-time monitoring of targeted drugs or gene delivery in a spatiotemporal controllable way, which has become a difficult problem for clinical molecular targeting, and imaging technology provides high spatiotemporal accuracy and non-invasive diagnosis and treatment mode. With the accelerated development of multidisciplinary integration trends such as medical imaging, nanomedicine, and synthetic biology, as well as the continuous innovation of molecular imaging and multimodal imaging technologies, the field of image-mediated targeted controlled release has entered a period of rapid development, but there are still low local aggregation of ** material tumors and single carrier function in this field.
1. Bottlenecks such as insufficient targeting and poor stability urgently need to establish a theoretical, technical and application system.
After more than 10 years, Professor Chen Zhiyi's team has completed the project of "Construction and Technological Innovation of Image-mediated Targeted Controlled Release of Malignant Tumors", based on the characteristics of imaging technology with integrated diagnosis and treatment and precise spatiotemporal controlled release, and carried out technical research from the three perspectives of "physical stimulation response, tumor microenvironment response, and active targeting of biological carriers", created an ultrasound-responsive targeted controlled release system, proposed a new strategy based on image-mediated drug cascade controlled release, and pioneered ultrasound-regulated tumor bacteria** system, and realize the transformation and promotion of achievements, and provide accurate imaging means for early diagnosis, targeting, monitoring and prognosis evaluation of malignant tumors.
Approved by the Ministry of Science and Technology and the National Science and Technology Award of the People's Republic of China and the National Science and Technology Award Office, the Huaxia Medical Science and Technology Award Award is one of the highest awards in China's medical field. The award focuses on individuals and units that have made outstanding contributions to promoting independent innovation, scientific and technological research, and industrialization of achievements in the field of medical science and technology. It is understood that a total of 448 recommended projects will be accepted for the 2023 Huaxia Medical Science and Technology Award, and after fierce competition, a total of 6 first prizes, 27 second prizes, 44 third prizes, 3 health management awards, 1 medical science popularization award, 2 international cooperation promotion awards, and 15 youth medical science and technology awards will be produced.
R&D and transformation of achievements is an important goal of scientific and technological innovation. The team will not forget its original intention, forge ahead, and continue to carry out research and technical research around the key problems existing in basic, clinical and translational research in medical imaging and related multidisciplinary research, so as to contribute to the construction of the discipline industry-university-research transfer chain and promote the high-quality development of the school. Professor Chen Zhiyi said.